Viruses 2012, 4(8), 1328-1334; doi:10.3390/v4081328
Article

Performance of VIDISCA-454 in Feces-Suspensions and Serum

1 Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, 1105AZ, Amsterdam, The Netherlands 2 Laboratory of Clinical Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, 1105AZ, Amsterdam, The Netherlands 3 Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Bioinformatics Laboratory, Academic Medical Center of the University of Amsterdam, 1105AZ, Amsterdam, The Netherlands 4 Biosystems Data Analysis, Swammerdam Institute for Life Sciences, University of Amsterdam, Science Park 904, 1098 XH, Amsterdam, The Netherlands These authors contributed equally to the work. Current address: CBS-KNAW Fungal Biodiversity Center, 3584 CT, Utrecht, The Netherlands.
* Author to whom correspondence should be addressed.
Received: 18 July 2012; in revised form: 13 August 2012 / Accepted: 15 August 2012 / Published: 22 August 2012
PDF Full-text Download PDF Full-Text [201 KB, uploaded 22 August 2012 11:48 CEST]
Abstract: Virus discovery combining sequence unbiased amplification with next generation sequencing is now state-of-the-art. We have previously determined that the performance of the unbiased amplification technique which is operational at our institute, VIDISCA-454, is efficient when respiratory samples are used as input. The performance of the assay is, however, not known for other clinical materials like blood or stool samples. Here, we investigated the sensitivity of VIDISCA-454 with feces-suspensions and serum samples that are positive and that have been quantified for norovirus and human immunodeficiency virus type 1, respectively. The performance of VIDISCA-454 in serum samples was equal to its performance in respiratory material, with an estimated lower threshold of 1,000 viral genome copies. The estimated threshold in feces-suspension is around 200,000 viral genome copies. The decreased sensitivity in feces suspension is mainly due to sequences that share no recognizable identity with known sequences. Most likely these sequences originate from bacteria and phages which are not completely sequenced.
Keywords: virus discovery; VIDISCA; diarrhoea; HIV-1; norovirus

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

de Vries, M.; Oude Munnink, B.B.; Deijs, M.; Canuti, M.; Koekkoek, S.M.; Molenkamp, R.; Bakker, M.; Jurriaans, S.; van Schaik, B.D.C.; Luyf, A.C.; Olabarriaga, S.D.; van Kampen, A.H.C.; van der Hoek, L. Performance of VIDISCA-454 in Feces-Suspensions and Serum. Viruses 2012, 4, 1328-1334.

AMA Style

de Vries M, Oude Munnink BB, Deijs M, Canuti M, Koekkoek SM, Molenkamp R, Bakker M, Jurriaans S, van Schaik BDC, Luyf AC, Olabarriaga SD, van Kampen AHC, van der Hoek L. Performance of VIDISCA-454 in Feces-Suspensions and Serum. Viruses. 2012; 4(8):1328-1334.

Chicago/Turabian Style

de Vries, Michel; Oude Munnink, Bas B.; Deijs, Martin; Canuti, Marta; Koekkoek, Sylvie M.; Molenkamp, Richard; Bakker, Margreet; Jurriaans, Suzanne; van Schaik, Barbera D. C.; Luyf, Angela C.; Olabarriaga, Silvia D.; van Kampen, Antoine H. C.; van der Hoek, Lia. 2012. "Performance of VIDISCA-454 in Feces-Suspensions and Serum." Viruses 4, no. 8: 1328-1334.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert